A Pharmacokinetic, Pharmacodynamic, Safety & Tolerability Study of

Updated 04/26/2024

Status Withdrawn

Clinical Trial Summary

The primary objective of this study is to evaluate the safety and tolerability of CERC-006 in adults (aged 18-31 years) with active, moderate to severe complex lymphatic malformations.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04994002
Study type	Interventional
Source	Cerecor Inc
Contact
Status	Withdrawn
Phase	Phase 1
Start date	September 3, 2021
Completion date	June 2022

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05871970` - Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age	Phase 2
	Terminated	`NCT04409145` - First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations	Phase 1/Phase 2
	Recruiting	`NCT03972592` - Topical Sirolimus in Cutaneous Lymphatic Malformations	Phase 2
	Recruiting	`NCT03243019` - Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations	Phase 2
	Recruiting	`NCT02399527` - Lymphatic Anomalies Registry for the Assessment of Outcome Data
	Completed	`NCT06257719` - Clinical Characteristics of Lymphatic Malformations
	Recruiting	`NCT04861064` - Weekly Sirolimus Therapy	Phase 2
	Recruiting	`NCT06275022` - A Prospective Study on the Treatment of cLM Based on ICG Imaging	N/A
	Recruiting	`NCT05563831` - National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
	Completed	`NCT04836884` - Vascular Anomaly Pathology and Genomics Biopsy Study	N/A
	Not yet recruiting	`NCT05983159` - A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	Phase 2